The Radboud Biobank has added one new sub-biobank to the collection: HEMLYM.
The Hematology-Lymphoma Biobank plans to collect blood, saliva, serum and cell-free DNA from every lymphoma patient, in addition to the residual material available from the Pathology department (tumor tissue), the Hematology department and the Laboratory of Hematology (bone marrow, peripheral blood and tumor tissue). In recent years, much progress has been made in the knowledge surrounding the processes involved in the development and progression of lymph node cancer and the response to therapy. The aim and ambition of HEMLYM is to improve the diagnosis and treatment of patients with lymphoma.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Quality certificate for the PBMC isolation method and cfDNA extraction method8 August 2023
Last year the Radboud Biobank participated for the first time in the IBBL Biospecimen Proficiency Testing program; an external quality assessment tool to verify the precision and accuracy of biospecimen testing methods and the efficiency of processing methods.read more
Theme Biobank and collections of Health RI launched a new project to develop a novel Dutch Biobank Standard30 March 2023
In February 2023 the theme Biobanks and Collections of Health-RI launched a new project entitled: “Dutch biobanking standard: towards harmonized, evidence-based collection, processing and storage of human biomaterials”.read more
Health-RI receives definitive follow-up funding from the National Growth Fund30 March 2023
The full funding of a total of 69 million euros has been definitively awarded to Health-RI, the national health data infrastructure for research and innovation.read more